Journal of Immunotherapy and Precision Oncology · 2018 · 12 citations · 5 references
Life SciencesDermatologyImmunologyClinical ImmunologyImmunopathologyImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune Checkpoint ModulationImmune CheckpointsImmunosuppressionMyelodysplastic SyndromesCutaneous Drug EruptionsDrug-induced Lichenoid EruptionImmune Checkpoint Inhibitor TherapyLichenoid Drug EruptionMyelodysplastic Syndrome TherapyMyelodysplastic Syndrome TreatmentPyoderma GangrenosumSystemic Disease Correlation
Abstract Pyoderma gangrenosum (PG) is an ulcerating neutrophilic dermatosis that is often associated with the underlying systemic disease. For example, PG is often a common presenting symptom in patients with hematologic malignancies, most commonly myelodysplastic syndrome (MDS). Here, we present the case of a patient who developed PG and a lichenoid drug eruption after the initiation of ipilimumab and nivolumab immune checkpoint inhibitor (ICPI) therapy. Lichenoid drug eruptions are well known to be associated with ICPI therapy, particularly nivolumab. However, only one case of PG has been reported in association with ipilimumab and no cases have ever been reported with nivolumab. Awareness that PG can be associated with ICPI therapy in patients with MDS can allow physicians to be better prepared to help in early recognition and early treatment to prevent the spread of disease.
5
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
Martina Sanlorenzo, Igor Vujic, Adil Daud et al. · JAMA Dermatology · 2015 · 452 citations · Full text
Medicine, Oncology, Pharmacology +15
Shelley Ji Eun Hwang, Giuliana Carlos, Deepal Wakade et al. · Journal of the American Academy of Dermatology · 2016 · 307 citations · Full text
Medicine, Dermatology, Oncology +17
Berenice Rudolph, Frank Staib, Esther von Stebut et al. · European Journal of Dermatology · 2014 · 29 citations
Medicine, Immunology, Oncology +17